Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cibus
San Diego, California, United Statescibus.com ↗
- Ownership
- Public · CBUS
- Employees
- ~159
- Development stage
- Other
01
Overview
Cibus has developed a proprietary non-transgenic gene-editing platform enabling rapid development of crop productivity and sustainability traits. Three out of six key trait programs have entered customer transfer/commercialization phases in canola and rice. The company is advancing additional disease resistance and productivity trait programs with promising early results, including durable white mold resistance in canola.
- Therapeutic areas
- Other
- Modalities
- Gene editing technology (specifically non-transgenic gene editing; RTDS platform)
- Industry
- Agriculture & AgTech
02
Partnerships
Multiple seed companies as customers/licensees—11 different seed companies referenced as partners/licensees for edited germplasm/traits.
03
Financials
- Market cap
- $87.1M
- Total revenue
- $3.6M
- Enterprise value
- $99.4M
Beyond the preview
Go deeper on Cibus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cibus.